You are here

MHRP at AIDS Vaccine 2013

September 27, 2013
Researchers from around the world will gather at the annual AIDS Vaccine conference October 7-10 in Barcelona. See the research MHRP and RV144 collaborators will present.

AIDS Vaccine, the annual scientific conference dedicated to AIDS vaccine research, will be held in Barcelona this October and will draw thousands of the best scientific minds in the field of HIV research. If you are attending, be sure to check out the MHRP presentations and RV144-related presentations by collaborating organizations. See the schedule below:

Tuesday, October 8

Comparative Analysis of Binding Antibody Responses elicited by a Cross-Section of Human HIV-1 Vaccine Clinical Trials (oral abstract, 11:00 am)
Dr. Shelly Krebs, MHRP

V2 Peptide Binding to HIV-1 Variants and Interaction of HIV-1 with 47 Integrin Receptor (poster)
Dr. Tina Peachman, MHRP

Comparable Antigenicity and Immunogenicity of Multimeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Clinical Development (poster)
Dr. Lindsay Wieczorek, MHRP

HLA Class II Genes Interact with the Immune Correlates from the RV144 Vaccine Efficacy Trial and Impact HIV-1 Acquisition (poster)

Dr. Rasmi Thomas, MHRP

Genetic and Immunological Evidence for a Role of Env-V3 Antibodies in the RV144 Trial (poster) 

Dr. Morgane Rolland, MHRP

Engaging and Recruiting MSM in HIV Research: Experiences from the Early HIV Capture Cohort Study in Kampala, Uganda (poster)

Lillian Mutengu, Makerere University Walter Reed Project, Uganda

Human HIV-1 Vaccine Induced Antibody Durability and Env IgG3 Responses* (poster)

Dr. Kelly E. Seaton, Duke University

A V2 Conformational Immunodominant Epitope Recognized by Human Monoclonal Antibodies* (poster)

Dr. Susan Zolla-Pazner, NYU School of Medicine

Antibody Responses to Recombinant gp120, gp70 V1V2 Proteins and Cyclic V2 Peptide in Thai Phase I/II Vaccine Trials using Different Vaccine Regimens (poster)

Dr. Chitraporn Karnasuta, AFRIMS, Thailand

Qualification of the Particle Diffusion Assay for Single Particle Tracking (poster)

Dr. Wiriya Rutvisuttinunt, AFRIMS, Thailand

Heterogeneity of anti-V2 ADCC Ab Responses and Implications for Vaccine Development* (poster discussion, 4:53 pm)

Dr. Justin Pollara, Duke University

Distinct HIV-Specific Antibody Fc-Profiles in RV144 and VAX003 Vaccinees* (poster discussion, 5:01 pm)

Dr. Amy Chung, Ragon Institute

Wednesday, October 9

Adenovirus 5 hexon-Specific CD4 T Cells are More Susceptible to HIV and Preferentially Depleted During Infection Compared to CMV-Specific CD4 T Cells (poster)

Dr. Haitao Hu, MHRP

Siglec-1 on Macrophages is a Major Infectivity Receptor for HIV-1: Differential Effects of GM-CSF and M-CSF on HIV-1 Entry and Replication (poster)

Dr. Mangala Rao, MHRP

Performance of the Determine HIV 1/2 Ag/Ab Combo Rapid Test on Serial Samples from an Acute Infection Study (RV217) in East Africa and Thailand (poster)

Leigh Anne Eller, MHRP

Stability of an an Acute HIV-1 Tanzanian Subtype C gp145 Envelope Protein for Clinical Development (poster)

Dr. Gary Matyas, MHRP

New Insight in HIV-1 Evolution during Acute Infection gained through Dense Sampling and Targeted Deep Sequencing (TDS) (poster)

Dr. Gustavo Kijak, MHRP

Recruitment and Retention of Urban Population in Vaccine Trials in Uganda (poster)

Dr. Hannah Kibuuka, Makerere University Walter Reed Project

Host-genetic Polymorphism in FcγRIIC Associated with HIV-1 Vaccine Efficacy in RV144 Trial* (poster)

Shuying S. Li, SCHARP

Preliminary Evaluation of Mucosal Immune Responses with Mucosal Tissue Explants in Humans Vaccinated with ALVAC/AIDSVAX B/E during the ongoing RV305 trial* (poster)

Dr. Carolina Herrera, Imperial College London

Evaluation of Peripheral and Mucosal Cellular Immune Responses induced by Late Boost Strategies in HIV-negative Participants prior enrolled in RV144 (poster)

Dr. Alexandra Schuetz, AFRIMS, Thailand

Investigation of Antibody Responses Induced in RV305 a Late Boost Vaccination of HIV-1 Uninfected Volunteers that Participated in RV144, a Thai Trial (poster)

Maj. Nicos Karasavvas, AFRIMS, Thailand

Early and Continuous Engagement of the CAB is Essential to the Successful Implementation of Invasive Procedures in Clinical Trials (poster)

Patchara Charuthamrong, AFRIMS, Thailand

Transcriptional profiling of RV144 Participants Reveals a Gene Expression
 Signature that Correlates with Immunogenicity* (poster)

Mark Cameron, Vaccine and Gene Therapy Institute Florida

Thursday, October 10

Looking Back to Move Forward: Understanding ALVAC/AIDSVAX Immune Responses (plenary, 11:20 am)

Lt. Col. Robert O'Connell, USAMC-AFRIMS, Thailand

*Denotes presentation by an RV144 collaborator